BioTuesdays

Category - Developments

Cellectar gets NCI grant for PDC platform

Cellectar Biosciences (NASDAQ:CLRB) has received initial notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant.The SBIR grant provides up to $2.3-million over 2 1/2 years from the...

Vital outlines plans for new Phase 3 ELAD trial

Vital Therapies (NASDAQ:VTL) has outlined plans for a possible new Phase 3 clinical trial designed to confirm ELAD’s safety and efficacy in alcohol-induced liver decompensation (AILD), including severe acute alcoholic...

Novadaq unveils SPY-Q Case Manager software

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has unveiled its SPY-Q Case Manager (SPY-QCM) software at the Symposium on Advanced Wound Care Fall 2015 meeting in Las Vegas.SPY-QCM is an image acquisition and analysis...

Subscribe

Sign up to our weekly BioTuesdays newsletter.